...: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer, compared with gemcitabine (GEM). However, whether PFS is a surrogate marker of OS in pancreatic cancer chemotherapy focusing on FOLFIRINOX...

...; Tsuyoshi Shirakawa; Kenji Mitsugi Introduction: Original FOLFIRINOX (oFFX) is more toxic than other regimens for patients with metastatic pancreatic cancer (mPC); therefore, a modified FFX (mFFX) regimen with a reduced dosage has been used in Japanese clinical practice. However, very few studies have...

... performance of serum methylated Homeobox A1 (m HOXA1 ) and methylated somatostatin (m SST ) using the CORD assay in combination with CA19-9 for pancreatic cancer using serum samples from 82 healthy individuals, 13 patients with benign pancreatic disease, 3 patients with branched-duct intraductal papillary...

... 24–42 months] versus 32 months [95% CI 29–34 months], p = 0.523). CA19-9 is a sialylated Lewis blood group antigen, the only guideline-recommended biomarker for pancreatic cancer. However, its clinical utility is impaired since CA19-9 levels can increase in conditions other than cancer, thereby...

...) is widely used as a useful biomarker of pancreatic cancer for monitoring the response to therapy, it is not recommended for screening of early pancreatic cancer because of its limited sensitivity for small tumors. Thus, it is critical to discover novel serum biomarkers to complement CA19-9 in order...

... (458,918) new cases of pancreatic cancer occur annually resulting in nearly as many deaths (432,242), the incidence of which is rising [ 1 ]. While cancer prognosis in recent decades has generally improved, that for pancreatic cancer has not. Many patients present with advanced disease upon diagnosis...

... for pancreatic cancer. Methods: A systematic literature search was performed in MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL). Only randomised controlled trials (RCTs) investigating the effect of adding cetuximab to standard chemotherapy in pancreatic cancer were included...

... at the RP2D. Median age was 61 years, and the majority of patients (94%) had stage IV disease. Overall response rates (complete or partial responses) were 2% for pancreatic cancer, 3% for breast cancer, and 0% for NSCLC. Median progression-free survival was 1.7, 1.7, and 2.0 months in the pancreatic cancer...

... trial of patients with advanced pancreatic cancer. Part A of the study was an intrapatient dose escalation lead-in portion in patients concurrently receiving gemcitabine, and in part B, patients were randomized 1: 1 to the recommended phase 2 dose combination PCI-27483–gemcitabine versus gemcitabine...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Antioxidant enzymes Microdissection MicroRNA miRNA Pancreatic cancer The transcription factor nuclear factor...

... Objective: To evaluate the efficacy and safety of alternate-day administration of S-1 as second-line chemotherapy for unresectable pancreatic cancer in a multicenter, randomized, phase II study. Methods: Patients with histologically proven, unresectable pancreatic cancer treated with chemotherapy...

...Hiroki Ishihara; Satoshi Yamashita; Ryosuke Amano; Kenjiro Kimura; Kosei Hirakawa; Takako Ueda; Yoshiki Murakami; Akihiro Tamori; Kazunari Tanabe; Norifumi Kawada; Atsushi Hagihara; Toshikazu Ushijima Objective: Pancreatic cancers are characterized by dense stroma. To estimate the degree...

... follow-up observational study should be performed. Re-examination, including ERP, should also be considered in cases with risk factors of pancreatic cancer, even if there is no change in MPD form. [email protected] 20 12 2017 © 2017 S. Karger AG, Basel 2017 Copyright / Drug...

...Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo Endoscopic ultrasound-guided pancreatic drainage (EUS-PD) was performed in a patient with unresectable pancreatic cancer who developed pancreatitis. In this case, EUS-PD was useful...

...Hiroki Sakamoto; Satoshi Harada; Nobu Nishioka; Kazuo Maeda; Takamasa Kurihara; Tateki Sakamoto; Kazuhide Higuchi; Masayuki Kitano; Yoshifumi Takeyama; Masafumi Kogire; Masatoshi Kudo Objectives: The early-stage pancreatic cancer (e-PC; stage I/II) detection rate is quite low at approximately 25...

..., Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513. Carcinoma Pancreatic cancer Targeted...

...Pietro Addeo; Edoardo Rosso; Pascal Fuchshuber; Elie Oussoultzoglou; Vito De Blasi; Gael Simone; Christine Belletier; Patrick Dufour; Philippe Bachellier Objective: To report the outcomes of surgical resection of borderline resectable (BL) and locally advanced (LA) ‘unresectable' pancreatic cancer...

...M. Michl; A.R. Haug; T.F. Jakobs; P. Paprottka; R.-T. Hoffmann; P. Bartenstein; S. Boeck; M. Haas; R.P. Laubender; V. Heinemann Objective: To analyze the clinical efficacy of 90 Y radioembolization in liver metastases from pancreatic cancer, to describe treatment toxicities and to identify...

...Shih-Hung Yang; Chih-Hung Hsu; Jen-Chieh Lee; Yu-Wen Tien; Sung-Hsin Kuo; Ann-Lii Cheng Objective: We investigated the association of the hedgehog pathway with nuclear factor (NF)-κB and clinical outcomes in pancreatic cancer patients. Methods: We analyzed tissue samples for the expression of NF-κB...

... for the molecular detection of circulating tumor cells (CTCs) in peripheral blood of pancreatic cancer patients. Methods: The presence of CTCs was evaluated in 34 pancreatic cancer patients before systemic therapy and in 40 healthy controls, through immunomagnetic enrichment, using the antibodies BM7 and VU1D9...